Lupin buys 21 generic brands from Shionogi to strengthen presence in Japanese market
India’s third largest drugmaker, Lupin (BSE: 5002571), will buy a portfolio of 21 generic brands from Japan-based Shionogi (TYO: 4507) at the cost of $150 million.
The move will help the company to strengthen its presence in the Japanese market, the second largest pharmaceutical market with a size of $110 billion. The acquisition will make Lupin rank sixth among generic companies in Japan. The 21 products, with combined sales of $90 million, will cover therapeutic areas including central nervous system (CNS), oncology, cardiovascular and anti-infectives.
"This acquisition marks Lupin's foray into the Japanese branded market, in line with our aspirations to build and strengthen our specialty business globally," Nilesh Gupta, managing director of Lupin, said in a statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze